Argitalpenak (14) Estefanía Pérez Lopez argitalpenak

2024

  1. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

    Bone Marrow Transplantation

  2. Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells

    Cytotherapy

2023

  1. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  2. Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study

    Cancers, Vol. 15, Núm. 5

2022

  1. Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review

    Advances in Rheumatology, Vol. 62, Núm. 1

2020

  1. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation

    Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 419-430

2017

  1. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

  2. Potential protective effect of Helicobacter pylori on the development of gastrointestinal GvHD

    Bone Marrow Transplantation, Vol. 51, Núm. 6, pp. 819-824

2014

  1. Diagnostic utility of bone marrow examination for the assessment of patients with fever of unknown origin: A 10-year single-centre experience

    Internal Medicine Journal, Vol. 44, Núm. 6, pp. 610-612

  2. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma

    Annals of hematology, Vol. 93, Núm. 10, pp. 1745-1753

  3. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

2013

  1. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

    Haematologica, Vol. 98, Núm. 3, pp. 437-443

2010

  1. Influence of the C677T mutation in methylenetetrahydrofolate reductase gene in venous thromboembolic disease

    Angiologia, Vol. 62, Núm. 6, pp. 225-231